Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Riluzole (Primary)
- Indications Pervasive child development disorders
- Focus Therapeutic Use
- 15 Jan 2021 Phase changed from II/III to Early Phase I. Time frame of primary endpoint clinical global impression improvement changed from week 14 to week 12
- 17 Apr 2017 Status changed from recruiting to completed.
- 31 Aug 2016 Planned End Date changed from 1 Jul 2015 to 1 Jul 2017.